XML 35 R25.htm IDEA: XBRL DOCUMENT
v3.25.1

Patent and Technology License Agreements (Details) - USD ($) |  |  |  | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | --- | ---
Dec. 15, 2025 | Jul. 15, 2025 | Sep. 30, 2021 | Mar. 31, 2025 | Mar. 31, 2024 | Mar. 31, 2025 | Mar. 31, 2024 | Mar. 31, 2023
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Fee expense |  |  |  |  |  |  | $ 90,000 | $ 90,000
Royalty rate, percentage |  |  |  |  |  | 15.00% |  |
Increasing annual royalties |  |  |  |  |  | $ 1,100,000 |  |
Research and development |  |  |  | $ 3,766,525 | $ 3,605,898 | 5,893,563 | $ 6,227,808 |
Upfront payment |  |  |  |  |  | 250,000 |  |
Development milestone payments |  |  |  | 22,000,000 |  | 22,000,000 |  |
Commercial sales milestones |  |  |  | 300,000,000 |  | 300,000,000 |  |
Forecast [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Revenue percentage | 2.00% |  |  |  |  |  |  |
Milestone payments | $ 2,197,892 |  |  |  |  |  |  |
Payment cost |  | $ 2,350,000 |  |  |  |  |  |
Citius Oncology [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Development milestone payments |  |  |  | 2,650,000 |  | 2,650,000 |  |
Patent and Technology License Agreement – Mino-Lok [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Annual minimum royalty payment |  |  |  |  |  | 100,000 |  |
Increasing annual royalties |  |  |  |  |  | 25,000 |  |
License Agreement Eterna [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Obligated pay amount |  |  |  | $ 51,000,000 |  | $ 51,000,000 |  |
Revenue percentage |  |  |  | 50.00% |  | 50.00% |  |
License Agreement Eterna [Member] | NoveCite [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Research and development |  |  | $ 5,000,000 |  |  |  |  |
Percentage of ownership additional shares |  |  |  |  |  | 25.00% |  |
License Agreement Eterna [Member] | License Agreement [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Outstanding equity |  |  | 75.00% |  |  |  |  |
License Agreement with Eisai [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  | $ 33,400,000 |  |
NetSalesPercentage |  |  |  |  |  | 50.00% |  |
Milestone payments |  |  |  |  |  | $ 5,900,000 |  |
Paying an extension fee |  |  |  | $ 10,000,000 |  | 10,000,000 |  |
License Agreement with Eisai [Member] | Forecast [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Development milestone payments |  | $ 2,535,318 |  |  |  |  |  |
LYMPHIR [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | 27,500,000 |  |
LYMPHIR [Member] | Citius Oncology [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
License payable |  |  |  |  |  | 5,000,000 |  |
FDA [Member] | Citius Oncology [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | 33,400,000 |  |
Dr. Reddy’s Laboratories, Ltd [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Development milestone payments |  |  |  | 22,500,000 |  | 22,500,000 |  |
Dr. Reddy’s Laboratories, Ltd [Member] | License Agreement with Eisai [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  | 40,000,000 |  |
Dr. Reddy’s Laboratories, Ltd [Member] | CTCL [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Development milestone payments |  |  |  | 40,000,000 |  | $ 40,000,000 |  |
Minimum [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Royalty rate, percentage |  |  |  |  |  | 10.00% |  |
Minimum [Member] | Royalty [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Royalty rate, percentage |  |  |  |  |  | 2.00% |  |
Minimum [Member] | License Agreement Eterna [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Royalty rate, percentage |  |  |  |  |  | 4.00% |  |
Minimum [Member] | License Agreement Eterna [Member] | Royalty [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Royalty rate, percentage |  |  |  |  |  | 8.00% |  |
Minimum [Member] | License Agreement with Eisai [Member] | Royalty [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Royalty rate, percentage |  |  |  |  |  | 10.00% |  |
Maximum [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Royalty rate, percentage |  |  |  |  |  | 15.00% |  |
Maximum [Member] | Royalty [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Royalty rate, percentage |  |  |  |  |  | 7.00% |  |
Maximum [Member] | Patent and Technology License Agreement – Mino-Lok [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Increasing annual royalties |  |  |  |  |  | $ 150,000 |  |
Maximum [Member] | License Agreement with Eisai [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Development milestone payments |  |  |  | $ 70,000,000 |  | $ 70,000,000 |  |
Maximum [Member] | License Agreement with Eisai [Member] | Royalty [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Royalty rate, percentage |  |  |  |  |  | 15.00% |  |
NoveCite [Member] | License Agreement Eterna [Member] |  |  |  |  |  |  |  |
Patent and Technology License Agreements [Line Items] |  |  |  |  |  |  |  |
Minority equity interest |  |  | 25.00% |  |  |  |  |

X
- Definition Represent the amount of license payable. + References No definition available. + Details
Name: | ctxr_LicensePayable
Namespace Prefix: | ctxr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment for development in process. + References No definition available. + Details
Name: | ctxr_MilestonePayments
Namespace Prefix: | ctxr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Net sales percentage. + References No definition available. + Details
Name: | ctxr_NetSalesPercentage
Namespace Prefix: | ctxr_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty rate. + References No definition available. + Details
Name: | ctxr_RoyaltyRate
Namespace Prefix: | ctxr_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21 Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details
Name: | us-gaap_Cash
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommercialPaper
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The current amount of expenditures for a real estate project that has not yet been completed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_DevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of fee payable for management of operations based on performance under arrangement, including, but not limited to, investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details
Name: | us-gaap_IncentiveFeePayable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 850 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details
Name: | us-gaap_ManagementFeeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow for loan origination associated cost which is usually collected through escrow. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentsOfLoanCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromRoyaltiesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=ctxr_CitiusOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctxr_PatentAndTechnologyLicenseAgreementMinoLokMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctxr_LicenseAgreementEternaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ctxr_NoveCiteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ctxr_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctxr_LicenseAgreementWithEisaiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ctxr_LYMPHIRMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ctxr_FDAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctxr_DrReddysLaboratoriesLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ctxr_CTCLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=ctxr_NoveCiteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |